前瞻全球产业早报：2025年新一线城市名单发布

Group 1 - Chengdu has topped the "2025 New First-tier City Charm Ranking" for 11 consecutive years, achieving a perfect score in four out of five dimensions [2] - The "2025 New Domain New Quality Innovation Competition" targets 169,000 specialized and innovative enterprises, aiming to identify 500 outstanding projects [3] - Honor has officially entered the robotics sector, showcasing a robot that can run at a speed of 4m/s, setting a new industry record [4] Group 2 - CATL is committed to continuous investment in solid-state batteries, with expectations for small-scale production by 2027 [5] - Pony.ai has signed a strategic cooperation agreement with Guangzhou Public Transport Group to advance the commercialization of autonomous driving [6][7] - DJI is set to enter the robotic vacuum market, with its first product expected to launch in June after four years of development [8] Group 3 - BYD has established a new automotive sales company in Changsha with a registered capital of 1 million RMB, focusing on new energy vehicle sales [9] - ByteDance will ban third-party AI programming tools internally, opting for its own tool, Trae, to mitigate data leak risks [10] - The European Union aims to reduce carbon emissions by 54% by 2030, slightly below its 55% target [11] Group 4 - SpaceX's Starship experienced a failure during its ninth test flight, but CEO Elon Musk noted significant progress compared to previous flights [12] - Volvo has temporarily halted production at its South Carolina plant due to supply chain issues related to a hardware component [13] - South Korea plans to invest approximately 480 billion KRW (around 349.1 million USD) in AI-related products and services this year [14] Group 5 - Nissan is seeking over 7 billion USD in funding with the assistance of the UK government to maintain operations [15] - Japan's parliament has passed its first law specifically addressing artificial intelligence, aimed at promoting development and preventing misuse [16] - Eli Lilly announced its acquisition of private company SiteOne Therapeutics to gain access to an experimental non-opioid pain medication [17]